TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has closed a non-brokered private placement offering of 576,923 common shares priced at $1.04 per common share (the "Common Shares") for gross proceeds of $600,000 CAD (the "Offering").

The final amount of the Offering was an increase of CAD $100,000 from the amount originally disclosed to the market on November 10, 2025. The proceeds of the Offering will be used by Arch as general working capital and for certain operating expenses that are not covered by the Company's human trial funding grants. The Offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including final approval from the TSX Venture Exchange.

The Offering involved the issuance of 480,923 Common Shares to an officer of the Company and therefore a "related party" (as such term is defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101")) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(a) of MI 61-101, as the fair market value of the Common Shares distributed and the consideration received from the related party in the Private Placement does not exceed 25% of the Company's market capitalization.

All Common Shares issued ...